CIP
TPTX

Chartwell Investment Partners’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Chartwell Investment Partners’s Portfolio TPTX Stock Details TPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-9,784
Closed -$736K – 436
2022
Q2 		$736K Buy
+9,784
New +$435K 0.03% 373
2022
Q1 		– Sell
-4,570
Closed -$218K – 447
2021
Q4 		$218K Sell
4,570
-148
-3% -$6.62K 0.01% 421
2021
Q3 		$313K Hold
4,718
– – 0.01% 423
2021
Q2 		$368K Buy
4,718
+45
+1% +$3.33K 0.01% 418
2021
Q1 		$442K Sell
4,673
-250
-5% -$29.7K 0.01% 403
2020
Q4 		$600K Sell
4,923
-1,115
-18% -$122K 0.02% 391
2020
Q3 		$527K Hold
6,038
– – 0.02% 391
2020
Q2 		$390K Sell
6,038
-2,202
-27% -$127K 0.02% 387
2020
Q1 		$368K Buy
+8,240
New +$438K 0.02% 376

Chartwell Investment Partners's TPTX Position: Q3 2022 in Review

Chartwell Investment Partners sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q3 2022, closing a stake of 9,784 shares — an estimated $736K sold.

Chartwell Investment Partners first reported a position in TPTX in Q1 2020 and held it in 9 quarters. The position peaked at $736K in Q2 2022. 0 funds tracked by Wall St. Rank hold TPTX as of Q3 2022.

  • Chartwell Investment Partners reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Chartwell Investment Partners sold 9,784 Turning Point Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $736K.
  • Chartwell Investment Partners first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q1 2020 and held it in 9 quarters.
  • Chartwell Investment Partners's Turning Point Therapeutics, Inc. Common Stock position peaked at $736K in Q2 2022.
  • 0 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Chartwell Investment Partners's 13F filing for Q3 2022, filed 27 Oct 2022.